ITGB8 Recombinant Monoclonal Antibody

Code: CSB-RA011892MA1HU

Rate （N/A）
Review （0）

Size:

50μl100μl

US$210

Quantity:

Species Reactivity: Human

Application: ELISA, IHC, FC

Send an Inquiry

Start an on-line Chat

Online ordering is currently available for U.S. customers only. For orders outside the U.S., please kindly submit an inquiry or start a chat with us.

Product Details
Related Products
Customer Reviews and Q&A
Target Background

Product Details

Uniprot NO.

P26012

Target Names

ITGB8

Alternative Names

Integrin beta-8 antibody; ITB8_HUMAN antibody; ITGB 8 antibody; ITGB8 antibody

Species Reactivity

Human

Immunogen

Recombinant Human ITGB8 protein

Immunogen Species

Homo sapiens (Human)

Conjugate

Non-conjugated

Clonality

Monoclonal

Isotype

hIgG1

Clone No.

30G12

Purification Method

Affinity-chromatography

Concentration

It differs from different batches. Please contact us to confirm it.

Buffer

Preservative: 0.03% Proclin 300
Constituents: 50% Glycerol, 0.01M PBS, PH 7.4

Form

Liquid
Note: We will preferentially ship the format that we have in stock, however, if you have any special requirement for the format, please remark your requirement when placing the order, we will prepare according to your demand.

Tested Applications

ELISA, IHC, FC

Recommended Dilution

Application	Recommended Dilution
IHC	1:50-1:200
FC	1:50-1:200

Protocols

ELISA Protocol Immunohistochemistry (IHC) Protocol Flow Cytometry (FC) Protocol

Storage

Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.

Lead Time

Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.
Note: All of our proteins are default shipped with normal blue ice packs, if you request to ship with dry ice, please communicate with us in advance and extra fees will be charged.

Usage

For Research Use Only. Not for use in diagnostic or therapeutic procedures.

Datasheet & COA

Antibody FAQs

Images

IHC image of CSB-RA011892MA1HU diluted at 1:50 and staining in paraffin-embedded human kidney tissue performed on a Leica BondTM system. After dewaxing and hydration, antigen retrieval was mediated by high pressure in a citrate buffer (pH 6.0). Section was blocked with 10% normal goat serum 30min at RT. Then primary antibody (1% BSA) was incubated at 4°C overnight. The primary is detected by a Anti-Human lgG, Fcy Fragment Specific labeled by HRP and visualized using 0.05% DAB.
IHC image of CSB-RA011892MA1HU diluted at 1:50 and staining in paraffin-embedded human endometrial cancer performed on a Leica BondTM system. After dewaxing and hydration, antigen retrieval was mediated by high pressure in a citrate buffer (pH 6.0). Section was blocked with 10% normal goat serum 30min at RT. Then primary antibody (1% BSA) was incubated at 4°C overnight. The primary is detected by a Anti-Human lgG, Fcy Fragment Specific labeled by HRP and visualized using 0.05% DAB.
Overlay Peak curve showing 786-O cells stained with CSB-RA011892MA1HU (red line) at 1:100. Then 10% normal goat serum to block non-specific protein-protein interactions followed by the antibody (1ug/1*10⁶cells) for 45min at 4℃. The secondary antibody used was Fluorescein (FITC) AffiniPure Goat Anti-Human IgG, Fcγ fragment specific at 1:200 dilution for 35min at 4℃.Control antibody (green line) was human IgG1 (1ug/1*10⁶cells) used under the same conditions. Acquisition of >10,000 events was performed.

Description

Integrin beta-8 plays a distinctive role among integrin family members, primarily functioning as a receptor for latent TGF-beta activation through its exclusive pairing with the alpha-v subunit. This specialized function positions ITGB8 as a critical regulator of TGF-beta bioavailability in tissues, with significant implications for developmental biology, fibrosis research, and tumor microenvironment studies. The protein's expression patterns in epithelial and neuronal tissues make it particularly relevant for investigators exploring tissue homeostasis and pathological remodeling processes.

This recombinant monoclonal antibody, clone 30G12, offers the reproducibility advantages inherent to sequence-defined production. Unlike traditional hybridoma-derived antibodies, recombinant manufacturing ensures consistent performance across lots, allowing researchers to establish reliable protocols without the variability that can complicate longitudinal studies or multi-site collaborations. The human IgG1 isotype format and affinity-chromatography purification contribute to a reagent suitable for demanding experimental workflows.

Validation studies demonstrate robust performance across multiple platforms. Immunohistochemistry applications have been confirmed in paraffin-embedded human kidney tissue and human endometrial cancer specimens at dilutions of 1:50 to 1:200, enabling detection in both normal and pathological contexts. Flow cytometry validation using 786-O renal carcinoma cells shows clear positive signal separation from isotype control, supporting cell surface detection studies at comparable dilutions.

This antibody serves researchers investigating integrin-mediated TGF-beta activation, epithelial biology, and cancer progression. The demonstrated performance in both tissue sections and live cell analysis provides flexibility for studies examining ITGB8 expression patterns, from archival clinical specimens to functional cell-based assays exploring integrin biology in disease contexts.

Customer Reviews and Q&A

■ Customer Reviews

Submit a Review here

Target Background

Function(From Uniprot)

Integrin alpha-V:beta-8 (ITGAV:ITGB8) is a receptor for fibronectin. It recognizes the sequence R-G-D in its ligands. Integrin alpha-V:beta-6 (ITGAV:ITGB6) mediates R-G-D-dependent release of transforming growth factor beta-1 (TGF-beta-1) from regulatory Latency-associated peptide (LAP), thereby playing a key role in TGF-beta-1 activation on the surface of activated regulatory T-cells (Tregs) (Probable). Required during vasculogenesis.

Gene References into Functions

ITGB8 is identified as a novel target of miR-26a-5p. PMID:29746867
our results indicate that miR-199a-3p enhances cisplatinsensitivity of ovarian cancer cells through downregulating ITGB8 expression, and miR-199a-3p may serve as a therapeutic target for the treatment of ovarian cancer patients with cisplatin-resistance. PMID:29436681
In cellular model, the microRNA-513a-3p was identified as a novel element targeting ITG-beta8, thereby controlling the protein level and its molecular function in the controlling of migration and pro-inflammatory environment. PMID:29204818
Among Greek and Polish patients with intracerebral hemorrhage, heterozygous individuals with the rs10251386 and the rs10239099 of the ITGB8 gene had significantly lower age of ICH onset compared to the wild-type genotypes. PMID:27476161
The results demonstrated that the hsa_circ_0046701/miR-142-3p/ITGB8 axis might play critical regulatory roles in the pathogenesis and development of glioma. PMID:29337055
Integrin beta8 was differentially expressed between Fibromyalgia patients and healthy controls. PMID:27157394
Integrin Beta8 plays a role in the motility of prostate cancer cells. PMID:25886373
data show that integrin beta 8, but not integrin beta 5 or integrin beta 6, protein expression is increased in liver specimens of patients with biliary atresia PMID:25079481
Brain metastases ITGB8 expression exhibits considerable heterogeneity according to tumor origin. PMID:24294359
Desmoglein-2 co-localizes with integrin-beta8 in N-MVECs. PMID:23874518
ITGB8 silencing may change lung cancer cells to a less invasive phenotype through alteration in the expression of metastasis-related genes. PMID:22753015
Deletion of the Itgb8 gene from retinal ganglia cells and Mu ller glia, but not astrocytes, results in highly abnormal vascular patterning and instability. PMID:22279205
Highly angiogenic and poorly invasive glioblastomas expressed low levels of beta8 integrin, whereas highly invasive glioblastomas with limited neovascularization expressed high levels of beta8 integrin. PMID:21859829
Interleukin-1beta induces increased transcriptional activation of the transforming growth factor-beta-activating integrin subunit beta8 through altering chromatin architecture. PMID:21878622
miR-93 promotes the growth of, and angiogenesis in astrocytomas, by suppressing, at least in part, integrin-beta8 expression. PMID:20956944
Transcription of the transforming growth factor beta activating integrin beta8 subunit is regulated by SP3, AP-1, and the p38 pathway PMID:20519498